Nanoscope Therapeutics to Update on MOGENRY BLA Progress at Cell &…

Event summary

Nanoscope Therapeutics' CSO Samarendra Mohanty to present at Cell & Gene Meeting on the Mesa 2026 on October 6, 2026.
Presentation will provide update on MOGENRY (MCO-010) Biologics License Application (BLA) under FDA review.
MOGENRY is a one-time, in-office optogenetic gene therapy for inherited retinal dystrophies.
Company has additional Phase 2/3 programs for Stargardt disease and geographic atrophy.
MOGENRY has received multiple regulatory designations including FDA Fast Track and Orphan Drug status.

The big picture

Nanoscope's presentation comes at a critical juncture as the company awaits FDA decision on its lead asset MOGENRY. The optogenetic gene therapy market is rapidly evolving, with increasing focus on treatments for inherited retinal dystrophies. Nanoscope's disease-agnostic approach positions it uniquely in this competitive landscape, but success will depend on regulatory approvals and clinical trial outcomes. The company's ability to secure partnerships and funding will also be key to its long-term strategy.

What we're watching

Regulatory Timeline: The pace at which the FDA will review and potentially approve MOGENRY's BLA will determine Nanoscope's commercialization timeline.
Clinical Expansion: Whether Nanoscope can successfully initiate and complete its Phase 3 trial for Stargardt disease in 2026 will be critical for expanding its product portfolio.
Market Positioning: How MOGENRY's one-time, in-office administration differentiates it from competitors in the retinal degeneration treatment space.